ELXMF (Nova Eye Medical) Growth Rank: 8 (As of Aug. 06, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELXMF Nova Eye Medical Ltd ELXMF
46 GF Score
Price $0.01
GF Value $0.02
! 4 Warning Signs
View Full Analysis

What is Nova Eye Medical Growth Rank?

Nova Eye Medical ELXMF -0.03% 46 Growth Rank is 8 as of Aug. 06, 2026, which is 100% above its 10-year median of 4.00. GuruFocus rates ELXMF with a GF Score™ of 46/100 and a GF Value™ of $0.02. The stock has 4 warning signs investors should review.

Nova Eye Medical has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Nova Eye Medical Growth Rank Related Terms

ELXMF vs ABT, SYK, MDT: Growth Rank Comparison

For the Medical Devices subindustry, Nova Eye Medical's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nova Eye Medical Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's Growth Rank distribution charts can be found below:

* The bar in red indicates where Nova Eye Medical's Growth Rank falls into.


ELXMF
46GF Score
Nova Eye Medical Ltd ELXMF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
Nova Eye Medical (ELXMF) has a Growth Rank of 8 as of Aug. 06, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Nova Eye Medical and its competitors. This is 100% above median its historical median of 4.00. Over the past decade, Nova Eye Medical's Growth Rank has ranged from 1.00 to 10.00.
Is Nova Eye Medical's Growth Rank too high?
Nova Eye Medical's current Growth Rank of 8 is 100% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Nova Eye Medical has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's Growth Rank compare to ABT and SYK?
Nova Eye Medical's Growth Rank of 8 can be compared against companies in the Medical Devices & Instruments industry. Historically, Nova Eye Medical's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Nova Eye Medical and its competitors. Nova Eye Medical's current Growth Rank is 8, which is 100% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current Growth Rank of 8. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current Growth Rank is 8, which is 100% above median its 10-year median of 4.00. Nova Eye Medical's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current Growth Rank is 8 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Eye Medical (ELXMF) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.

Key valuation signals for ELXMF:

  • Growth Rank: 8 (100% above median its 10-year median of 4.00)
  • GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Other Exchanges EYE:Australia
Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
46GF Score

Get the complete analysis for ELXMF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price
$0.02
GF Value